Helicobacter pylori and other bacterial components (H. pylori)

Helicobacter pylori is a Gram-negative, spiral-shaped bacterium that specifically colonizes the human gastric mucosa (NIH, 2023). It is recognized as a major cause of chronic gastritis, peptic ulcer disease, and is a significant risk factor for gastric adenocarcinoma and mucosa-associated lymphoid tissue (MALT) lymphoma (PubMed: 30033115). The "other bacterial components" mentioned typically include virulence factors such as the cytotoxin-associated gene A (CagA) and vacuolating cytotoxin A (VacA), which are instrumental in modulating the host immune response and causing cellular damage (UniProt: P12914). While the bacterium itself is the focus of eradication therapy, it is not a single molecular target; rather, drugs target specific bacterial enzymes and structures like the cell wall or ribosomes (StatPearls: NBK544281). Standard treatment involves "triple therapy" or "quadruple therapy," combining multiple antibiotics with proton pump inhibitors to increase gastric pH and enhance drug stability (PubMed: 31217112). Monitoring for successful eradication is typically performed using non-invasive tests such as the urea breath test or stool antigen assays (Mayo Clinic, 2023). The emergence of multi-drug resistant strains remains a significant challenge in clinical management (WHO, 2017).

Other names

H. pyloriHelicobacter pylori antigensBacterial pathogensGastric bacterial components

Therapeutic agents target various bacterial processes including cell wall synthesis inhibition, protein synthesis inhibition, DNA disruption, and the neutralization of gastric acidity to facilitate antibiotic activity.